The Recall Desk
SevereFDA (Drugs)·D-1089-2015·Announced 2015-07-15

Teva Recalls Adrucil Fluorouracil Injection Due to Particulate Matter

Teva Pharmaceuticals is recalling Adrucil (fluorouracil injection) vials due to the presence of black particulate matter, including silicone rubber and drug crystals.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The agency classification is FDA Class I, which mandates a minimum severity score of 4 per the rubric.

Plain-English summary

Teva Pharmaceuticals USA is recalling 6,195 vials of Adrucil (fluorouracil injection, USP) Pharmacy Bulk Package, 5 g/100 mL (50 mg/mL). The product is intended for intravenous use only and is distributed nationwide.

The recall was initiated because black particulate matter was identified in the product. This matter consists of an aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals.

Healthcare providers and pharmacies should stop using the affected vials and follow Teva's instructions for return or destruction. Patients who have received the medication should contact their healthcare provider if they have concerns.

The recalled product

Product
Adrucil (fluorouracil injection, USP) Pharmacy Bulk Package Not for Direct Infusion, 5 g/100 mL (50 mg/mL), For Intravenous Use Only, Rx Only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-3019-11
Affected units
6,195

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (11)

  • Lot #s: 31317858B
  • Exp 11/2015
  • 31317899B
  • 31317906B
  • 31317958B
  • 31317959B
  • 31318103B
  • 31318137B
  • Exp 12/2015
  • 31318533B
  • Exp 07/2016

Distribution

Distributed nationwide across the United States.